Nonpeptide oxytocin agonists

被引:12
作者
Ashworth, Doreen M.
Batt, Andrzej R.
Baxter, Andrew J.
Broqua, Pierre
Haigh, Robert M.
Hudson, Peter
Heeney, Celine M. S.
Laporte, Regent
Penson, Andrew
Pitt, Gary R. W.
Robson, Peter A.
Rooker, David P.
Tartar, Andre L.
Yea, Chris M.
Roe, Michael B.
机构
[1] Ferring Res Ltd, Southampton SO16 7NP, Hants, England
[2] Ferring Pharmaceut AS, DK-2300 Copenhagen S, Denmark
[3] Ferring Res Inst Inc, San Diego, CA 92121 USA
[4] Fac Sci Pharmaceut & Biol, F-59006 Lille, France
关键词
D O I
10.1358/dof.2006.031.04.980655
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxytocin is a neurohypophyseal hormone that acts at the oxytocin receptor localized both peripherally and centrally and is particularly highly expressed in the pregnant human myometrium. Synthetic oxytocin has long been used to induce labor and oxytocin antagonists have been introduced for the treatment of preterm labor. New compounds are described that are potent, selective and efficacious oxytocin receptor agonists with potential utility in promoting labor and for the treatment of conditions such as male and female sexual dysfunction. These new agents may also be useful as tools for further elucidating the roles of the oxytocin receptor system. Furthermore, as they are nonpeptidic in nature, they may offer advantages over peptide oxytocin analogues in terms of oral availability and central penetration. This article describes the various approaches that have been used to discover such compounds. Compounds such as 27, the first nonpeptide oxytocin agonists reported, are currently being investigated as pharmacological tools in animal models of oxytocin activity.
引用
收藏
页码:345 / 353
页数:9
相关论文
共 26 条
  • [1] Andersson KE, 2001, PHARMACOL REV, V53, P417
  • [2] Can peptides be mimicked?
    Beeley, NRA
    [J]. DRUG DISCOVERY TODAY, 2000, 5 (08) : 354 - 363
  • [3] 2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics
    Borthwick, AD
    Davies, DE
    Exall, AM
    Livermore, DG
    Sollis, SL
    Nerozzi, F
    Allen, MJ
    Perren, M
    Shabbir, SS
    Woollard, PM
    Wyatt, PG
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) : 6956 - 6969
  • [4] BRAMER SL, 2002, CLIN PHARM THER, V71
  • [5] WAY-VNA-932.: Treatment of central diabetes insipidus, Treatment of nocturnal enuresis, Treatment of nocturia, Vasopressin V2 agonist.
    Caggiano, TJ
    [J]. DRUGS OF THE FUTURE, 2002, 27 (03) : 248 - 253
  • [6] Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor
    Cirillo, R
    Tos, EG
    Schwarz, MK
    Quattropani, A
    Scheer, A
    Missotten, M
    Dorbais, J
    Nichols, A
    Borrelli, F
    Giachetti, C
    Golzio, L
    Marinelli, P
    Thomas, RJ
    Chevillard, C
    Laurent, F
    Portet, K
    Barberis, C
    Chollet, A
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) : 253 - 261
  • [7] Coomarasamy Aravinthan, 2002, Med Sci Monit, V8, pRA268
  • [8] Dalton L, 2005, CHEM ENG NEWS, V83, P94
  • [9] Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section
    Dansereau, J
    Joshi, AK
    Helewa, ME
    Doran, TA
    Lange, IR
    Luther, ER
    Farine, D
    Schulz, ML
    Horbay, GLA
    Griffin, P
    Wassenaar, W
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (03) : 670 - 676
  • [10] Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
    Diamond, LE
    Earle, DC
    Rosen, RC
    Willett, MS
    Molinoff, PB
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (01) : 51 - 59